EUVIMEDAtrasti EUVIMED
KohortenstudieOpen access · CC BY-NC-ND 4.0

Neonatal outcome following metformin‐treated gestational diabetes mellitus: A population‐based cohort study

Johanna Molin iD, Magnus Domellöf, Christel Häggström, Eszter Vanky, Itay Zamir, Eva Östlund, Marie Bixo

Acta Obstetricia et Gynecologica Scandinavica · 2024

DOI: 10.1111/aogs.14787 ↗

At a glance

Kohortenstudie in Acta Obstetricia et Gynecologica Scandinavica, 2024. Written by Johanna Molin and 6 co-authors. Institution: Department of Clinical Sciences, Umeå University, Umeå, Sweden. Major MEDLINE topics: Metformin, Diabetes, Gestational, Premature Birth, Hypoglycemia. Cited 4 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Västerbotten county council, Umeå University, Västerbotten Läns Landsting.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Introduction

Neonatal hypoglycemia is a common complication associated with gestational diabetes and therefore relevant to consider in evaluations of maternal treatment. We aimed to investigate the risk of neonatal hypoglycemia in offspring exposed to metformin treatment alone (MT) or combined with insulin (MIT) in comparison with nutrition therapy alone (NT), and insulin treatment alone (IT). In addition, we investigated MT in comparison with MIT. Secondary outcomes included neonatal anthropometrics, respiratory morbidity, hyperbilirubinemia, 5‐min Apgar score, and preterm birth. Material and methods This Swedish population‐based cohort included 16 181 women diagnosed with gestational diabetes, and their singleton offspring born in 2019–2021. We estimated risk as adjusted odds ratio (aOR) with 95% confidence interval (CI), using individual‐level, linkage register‐data in multivariable logistic regression models.

Results

In the main analysis, MT was associated with a lower risk of neonatal hypoglycemia vs NT (aOR 0.85, 95% CI: 0.74–0.96), vs MIT (0.74 [0.64–0.87]), and vs IT (0.47 [0.40–0.55]), whereas MIT was associated with a similar risk of neonatal hypoglycemia vs NT (1.14 [0.99–1.30]) and with lower risk vs IT (0.63 [0.53–0.75]). However, supplemental feeding rates were lower for NT vs pharmacological treatments ( p < 0.001). In post hoc subgroup analyses including only exclusively breastfed offspring, the risk of neonatal hypoglycemia was modified and similar among MT and NT, and higher in MIT vs NT. Insulin exposure, alone or combined with metformin, was associated with increased risk of being large for gestational age. Compared with NT, exposure to any pharmacological treatment was associated with significantly lower risk of 5‐min Apgar score < 4. All other secondary outcomes were comparable among the treatment categories.

Conclusions

The risk of neonatal hypoglycemia appears to be comparable among offspring exposed to single metformin treatment and nutrition therapy alone, and the lower risk that we observed in favor of metformin is probably explained by a difference in supplemental feeding practices rather than metformin per se. By contrast, the lower risk favoring metformin exposure over insulin exposure was not explained by supplemental feeding. However, further investigations are required to determine whether the difference is an effect of metformin per se or mediated by other external factors.

Subjects

MeSH terms (MEDLINE)

MetforminDiabetes, GestationalPremature BirthHypoglycemiaInfant, Newborn, DiseasesPregnancyInfant, NewbornFemaleHumansChild, PreschoolHypoglycemic AgentsCohort StudiesInsulinPregnancy Outcome

Author keywords

gestational diabetes mellitusmetforminneonatal hypoglycemianeonatal outcomepopulation‐basedregister‐based

Substances

MetforminHypoglycemic AgentsInsulin

Authors and institutions

  • Department of Clinical Sciences, Umeå University, Umeå, Sweden.
  • Northern Registry Center, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Obstetrics and Gynecology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Clinical Sciences and Education, Södersjukhuset, Karolinska Institute, Stockholm, Sweden.

ORCID profiles: Johanna Molin

Funding

  • Västerbotten county council
  • Umeå University
  • Västerbotten Läns Landsting
  • Umeå Universitet

Cite

APA

Molin, J., Domellöf, M., Häggström, C., Vanky, E., Zamir, I., Östlund, E., & Bixo, M. (2024). Neonatal outcome following metformin‐treated gestational diabetes mellitus: A population‐based cohort study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14787

Vancouver

Molin J, Domellöf M, Häggström C, Vanky E, Zamir I, Östlund E, et al. Neonatal outcome following metformin‐treated gestational diabetes mellitus: A population‐based cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2024. doi:10.1111/aogs.14787

BibTeX
@article{Molin2024,
  author = {Molin, Johanna and Domellöf, Magnus and Häggström, Christel and Vanky, Eszter and Zamir, Itay and Östlund, Eva and Bixo, Marie},
  title = {Neonatal outcome following metformin‐treated gestational diabetes mellitus: A population‐based cohort study},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2024},
  doi = {10.1111/aogs.14787}
}
Start for free →